Aura Biosciences (AURA)
(Real Time Quote from BATS)
$6.85 USD
+0.01 (0.15%)
Updated Aug 7, 2025 10:10 AM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AURA 6.85 +0.01(0.15%)
Will AURA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AURA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AURA
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
AURA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for AURA
3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside Potential
Aura Energy Advances Tiris Uranium Project with DFC’s ESIA Publication
Aura Biosciences Holds 2025 Annual Stockholders Meeting
Aura Energy to Release Shares from Escrow, Boosting Market Liquidity
Aura Energy Announces Strategic Development to Boost Market Position